27P - Outcomes analysis of the effect of an educational activity on the knowledge and confidence of oncologists regarding emerging antibody drug conjugates for the treatment of breast cancer

Background

The objective of this study was to assess the effect of an educational activity on the knowledge of oncologists regarding the rationale for using next-generation antibody drug conjugates (ADCs) for the treatment of breast cancer and the latest data from clinical trials.

Methods

This CME activity consists of a 2000-word article presenting expert insights in an interview style. Effectiveness of this education was assessed with a repeated-pairs pre-/post-assessment study design using 3 knowledge questions and 1 confidence question, in which each individual served as their own control. A paired sample t-test assessed mean differences in average number of correct responses pre- to post-assessment, and a McNemar’s test assessed significant improvement at question level. P values <.05 are statistically significant. The activity launched on January 27, 2022, with data collected through to April 1, 2022.

Results

By June 22, 2022 this activity had reached 1,019 physicians of whom 375 were oncology specialists (41% from Europe, 22% from Asia, 21% from Middle East and North Africa, and 13% from Latin America). Sixty-seven oncologists who completed all assessment questions were included in the study analysis. The average knowledge of oncologists increased significantly from 45% pre to 77% post-education (P < .001) as assessed by correct responses to the knowledge questions. There was a significant improvement in the knowledge of the following learning objectives as shown in the table below. Table: 27P

There was a measurable improvement in confidence in around 55% of oncologists regarding understanding of the treatment implications of the latest clinical trial data, and a 71% average confidence shift for those whose confidence had improved.

Conclusions

This study showed a positive educational impact of a 2000-word article presenting expert insights in an interview style, on the latest developments regarding emerging ADCs for the treatment of breast cancer. Further education is needed to update physicians on new data and guideline recommendations as these evolve in the future

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Medscape.

Funding

The educational activity was supported by an independent educational grant from Daiichi Sankyo.

Disclosure

N. Dorkhom, D. Grainger, Y. Ren: Financial interests, Personal, Full or part-time Employment: Medscape.